Scientists reported mechanistic data linking rare vaccine‑associated cardiomyositis to immune cell activity driven by elevated chemokines CXCL10 and interferon‑γ (IFN‑γ). The paper, published in Science Translational Medicine, demonstrated that blocking CXCL10 and IFN‑γ reduced muscle cell damage in vitro and attenuated cardiomyositis in animal models. Authors proposed targeted modulation of these mediators could mitigate the small risk of cardiac inflammation following certain mRNA vaccinations. The findings supply molecular targets for safety research and may inform risk‑reduction strategies while regulatory assessments continue.